Yanyan Liu

9PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 09, 2026
Translational Insights From the Molecular Landscape to Precision Therapy in Peripheral T-Cell Lymphoma: Integrating Multi-Omics and Artificial Intelligence.

|Jan 28, 2026
Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.

Liqiong Xue, Yaqian Han, Qingyuan Zhang

|Apr 02, 2025
Advances in Personalized Treatment and Prognostic Factors of Follicular Lymphoma.

Shijia Cheng, Yanyan Liu

|Jan 08, 2024
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study.

Yuqin Song, Zhengming Jin, Zhi-Ming Li

|Mar 30, 2023
Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.

Huiqiang Huang, Rong Tao, Siguo Hao

|Apr 29, 2022
MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.

Wenping Zhou, Yuanlin Xu, Jiuyang Zhang

Pageof 2

Frequent Collaborators

3 joint publications

Zheng Yan

2 joint publications

Zhiming Li

1 joint publications

Wenping Zhou

1 joint publications

Yuanlin Xu